^
Association details:
| Biomarker: | CCDC6‐RET fusion + TERT promotor mutation |
|---|---|
| Cancer: | Thyroid Gland Anaplastic Carcinoma |
| Drug: | Retevmo (selpercatinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A CASE OF RET POSITIVE METASTATIC ANAPLASTIC THYROID CARCINOMA WITH EXCELLENT RESPONSE TO RET INHIBITOR THERAPY
Published date:
09/20/2023
Excerpt:
We present a case of a 46 year old female patient who presented with a new left‐sided neck mass associated with dysphonia and biopsy revealed undifferentiated carcinoma of the thyroid….Next‐Generation Sequencing (NGS) revealed both CCDC6‐RET and TERT promotor mutations. The patient was observed post‐operatively and ultimately was started on RET inhibitor (Selpercatinib) after 3 month interval imaging revealed increasing nodal, pulmonary and new bone metastases. After the initiation of Selpercatinib, subsequent 3 month interval imaging revealed near complete resolution of her disease. We present a unique case of a young woman with metastatic ATC and an excellent response to targeted RET inhibition.
